A Preliminary Trial Of Serratiopeptidase In Patients With Carpal Tunnel Syndrome
Effect | Decrease |
Trial Design | Non-controlled trial |
Trial Length | 1-6 months |
Number of Subjects | 20 |
Sex | Both Genders |
Age Range | 30-44, 45-64 |
Body Types | Overweight |
Supplementation of serrapeptase (20mg) daily after an initial course of nimesulide was able to reduce symptoms of carpal tunnel syndrome in 65% of patients studied, but this trial failed to have a placebo group (and even then, is confounded by the initial course of nimesulide).